© 2026 Biohaven, Ltd. All rights reserved. Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY CAMERON Living with Graves’ Disease Corporate Presentation November 2026
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Biohaven Ltd. (the “Company”) and our planned and ongoing trials (including those for our taldefgrobep alfa, opakalim, BHV-2100, BHV-8000, BHV-8100, BHV-1300, BHV-1310, BHV-1400, BHV-1510, BHV-1530 and BHV-1600 development programs), the timing of and the availability of data from our clinical trials, the timing of and our decisions to proceed with our planned regulatory filings, the timing of and our ability to obtain regulatory approvals for our product candidates, the clinical potential utility of our product candidates, alone and as compared to other existing potential treatment options, and the potential advancement of our early phase programs, including BHV-1955, BHV- 8200, BHV-2110, BHV-1490, BHV-1420, BHV-1440, BHV-6500 and BHV-1500. The use of certain words, including “continue”, “plan”, “will”, “believe”, “may”, “expect”, “anticipate,” and similar expressions, is intended to identify forward -looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of our development candidates are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the Food and Drug Administration, including those regarding the resubmission of our new drug application for troriluzole for SCA; the timing and outcome of expected regulatory filings Biohaven’s compliance with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates; and the effectiveness and safety of Biohaven's product candidates, including open label clinical data in ongoing studies. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation. Additional important factors to be considered in connection with forward-looking statements are described in the Company’s filings with the Securities and Exchange Commission, including within the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. This presentation also contains market data and other information based on industry publications, reports by market research firms or published independent sources. Some market data and information are also based on the Company’s good faith estimates, which are derived from management’s knowledge of i ts industry and such independent sources referred to above. November 2026 Biohaven Corporate Presentation2
AAb, Autoantibody. November 2026 Biohaven Corporate Presentation3 PRECLINICAL PHASE 1 PHASE 1B/PHASE 2 PHASE 3 MARKET GLUTAMATE Troriluzole BHV-4157 Spinocerebellar Ataxia INFLAMMATION & IMMUNOLOGY IgG Degrader BHV-1300 Common Disease (Graves’, RA) Gd-IgA1 Degrader BHV-1400 IgA Nephropathy β1AR AAb Degrader BHV-1600 Peripartum Cardiomyopathy TYK2/JAK1 Inhibitor (brain-penetrant) BHV-8000 Parkinson’s Disease ION CHANNEL Kv7 Activator Opakalim Focal Epilepsy TRPM3 Antagonist BHV-2100 Pain Disorders MYOSTATIN ACTIVIN Taldefgrobep Alfa BHV-2000 Obesity ONCOLOGY Trop2 ADC +/- PD-1 BHV-1510 Advanced or Metastatic Epithelial Tumors FGFR3 ADC BHV-1530 Urothelial Cancer and Other Tumors PRE-CLINICAL DEGRADERS IgG Degrader BHV-1310 Rare Disease (Myasthenia Gravis) BHV-1320 Immune-Mediated Disease IgG4 Degrader BHV-1450 Pemphigus, MuSK MG, LGI-1 Encephalit is PLA2R AAb Degrader BHV-1420 Membranous Nephropathy TSHR AAb Degrader BHV-1440 Graves' Disease and TED Proinsulin AAb Degrader BHV-6500 Type 1 Diabetes IgM Degrader BHV-1490 IgM Neuropathy, Waldenstrom’s EMERGING TARGETS PKM2 Activator BHV-8100 Neurodegenerative Diseases Intranasal Oxytocin BHV-1955 Tinnitus
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Targeting the Root Cause of Autoimmune Disease DEGRADERS: MoDE AND TRAP
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Innovation in Protein Degradation: Harnessing Hepatic ASGPR for Efficient and Safe Removal of Circulating Pathogenic Targets November 2026 Biohaven Corporate Presentation5 MoDE and TRAP degraders bind circulating target and efficiently deliver to ASGPR on hepatocytes DEGRADATION TARGET HEPATOCYTE ASGPRs* ON HEPATOCYTE Internalized target is rapidly degraded in hepatic lysosomes ASGPRs are rapidly recycled 1 3 2 MoDE and TRAP optimized for patient-friendly autoinjector delivery BIFUNCTIONAL MoDE DEGRADERSDEGRADERS *Stylistic representation ASGPR, asialoglycoprotein receptor
November 2026 Biohaven Corporate Presentation6 First Extracellular Protein Degraders in the Clinic Demonstrate Rapid and Robust Pharmacodynamic Effects and Compelling Safety in Nearly 200 Individuals Dosed MoDE and TRAP DE GRAD ERS BHV-1400 BHV-1300 Safe Well-tolerated Highly selective Deep and rapid lowering Patient outcomes Pivotal trials 2026
B H V - 1 3 0 0 IgG degrader Graves’ disease · RA Sjögren's · Biologic failures >1M patients | $7.6B MoDE B H V - 1 4 0 0 TRAP Gd-IgA1 degrader IgA nephropathy ~133K patients | $5.0B November 2026 Biohaven Corporate Presentation7 B H V - 1 4 5 0 ~92K patients $2.6B IgG4 degrader Pemphigus vulgaris MuSK MG IgG4-RD CIDP MoDE and TRAP Degraders ADDRESSABLE PATIENTS >2M across lead programs (US) PIPELINE ASSETS 8+ BHV degrader programs PEAK SALES POTENTIAL $30B+ combined gross sales Addressable patients for each degrader based on internal assessment of potential patient population. Peak sales potential based on addressable patients for each degrader and internal assessment of gross revenue potential (prior to GTN adjustments or any adjustments associated with clinical risk), adjusted for estimated market share / market penetration. B H V - 6 5 0 0 Pro-Insulin/Insulin AAB degrader B H V - 1 4 4 0 TSHR AAb degrader Graves’ disease Thyroid eye disease B H V - 1 3 1 0 ~400K patients $11.1B IgG Degrader gMG Systemic sclerosis AE ITP B H V - 1 4 9 0 ~42K patients $1.7B IgM degrader Cold agglutinin disease Anti-MAG Waldenström's ~41K patients $1.3B PLA2R AAb Degrader Membranous nephropathy (MN) B H V - 1 4 2 0
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY BHV-1300 IgG antibody Targeting the Root Cause of Graves’ Disease IgG MoDE DEGRADER: BHV-1300
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Demographics: Graves’ Disease Impacts 1% of the Global Population November 2026 Biohaven Corporate Presentation9 About 4 out of 5 cases of hyperthyroidism in the United States are caused by Graves’ disease.1 Worldwide incidence of Graves’ disease2 1. Akram. Journal of Surgical Research. 2020. 2. McLeod. Endocrine, 2012. United States F: 38/100K per уear 1989–2001 United Kingdom F: 50/100K per уear 1972–1993 Sweden F/M: 21/100K per уear 2003–2005 Denmark F/M: 31/100K per уear 1997–2000 Slovenia F/M: 28/100K per уear 1999 Northern China F/M: 120/100K per уear 1994–2004 Graves’ disease affects nearly 1 in 100 Americans.1 DEGRADERS
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY experience 5+ symptoms experience 4+ symptoms report multiple symptoms (≥2) The Under-Recognized Burden of Graves' Disease1 November 2026 Biohaven Corporate Presentation10 43% 43% 54% 64% 64% 64% 93% Insomnia Bulging/irritated eyes Depression Rapid heartbeat Anxiety Palpitations Fatigue 1. Patient Burden in Graves’ Disease: Results From a Mixed Methods Survey DEGRADERS 93% 79% 72% Courtnay Living with Graves’ disease Current treatments achieve biochemical control but do not address the underlying antibody-driven disease, antibodies continue to circulate, targeting the thyroid, orbit, brain, and crossing the placenta KEY POINT Even among biochemically well-controlled patients, 75% report recurring symptoms — fatigue, palpitations, anxiety, weight gain
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Current Treatments for Graves’ Disease CONSERVATIVE Use of thionamides (ATDs, like methimazole, carbimazole, and propylthiouracil (PTU) Aplastic anemia, agranulocytosis, peripheral neuritis, liver issues, secreted in breastmilk Use of steroids November 2026 Biohaven Corporate Presentation11 1 2 TREATMENTS FOR GRAVES’ DISEASE I- 1 3 1 R a d ia ti o n S u rg e ry A T D s S te ro id s C O N S E R V A T IV E A B L A T IV E ABLATIVE Surgical removal of the thyroid Lifelong T4 replacement, surgical complications Use of I-131 radiation treatment Cannot use in pregnancy, TED worsens 3 4 DEGRADERS
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYBHV-1300 MoDE Targets the Root Cause of Graves' Disease and TSHR Autoantibody-Driven Diseases November 2026 Biohaven Corporate Presentation12 DEGRADERS E X C E S S H O R M O N E S T3 T4 TSHR AUTOANTIBODY DRIVEN DISEASES Thyroid eye disease Thyroid dermopathy Graves’ embryopathy Graves’ disease BHV-1300 degrades disease- causing TSHR-IgG1 antibodies BHV-1300 S TA B I L I Z E D H O R M O N E S T3 T4
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYNot an FcRn Inhibitor: Biohaven IgG MoDE Degrader Differentiates as a Novel MOA, Potential Paradigm-Shifting Therapy z 83% IgG LOWERING BY DAY 18 DID NOT INCREASE HEADACHES DID NOT INCREASE CHOLESTEROL SMALL MOLECULE AUTOINJECTOR ADMINISTRATION IN PIVOTAL TRIALS IgG antibody DEGRADERS 1. Median of the maximal total IgG % change from baseline 2. 84% IgG lowering (twice the labeled frequency) in Phase 1: Ling. Clin Pharmacol Ther. 2019. 3. Howard, Jr. ADAPT (SC) Data – 2024; 4. Ulrichts. J. Clin. Invest. 2018. 5. MAD data unavailable. MG Data from Bril, Lancet Neurology. 2023 – MyCarinG study. • Approximately 61% IgG lowering at week 4 (VYVGART Hytrulo® in MG trial)3 (average 75% in MAD)4 • Prefilled syringe • Cyclical dosing can lead to symptom rebound Vyvgart® • 74.6% IgG lowering after load, 68.8% in maintenance in Vivacity MG-31,2 • IV infusion • Increased cholesterol (24%), muscle spasms (12%), edema (12%) IMAAVY • Approximately 76% IgG lowering in the MycarinG study5 • Healthcare administered SC infusion • 44% headaches • Cyclical dosing can lead to symptom rebound Rystiggo® BHV-1300 Biohaven Corporate Presentation13 November 2026
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYBHV-1300 MoDE Deeply Removes Disease-Driving TSHR Autoantibody and Normalizes Thyroid Hormones November 2026 Biohaven Corporate Presentation14 Preliminary data from ongoing study, analysis conducted May 22, 2026. Data represents mean and standard error concentration o f TRAb, Free T4, and Free T3 in the three consecutive overt hyperthyroid participants with Graves’ disease. Participants were dosed with BHV-1300 SC 1000 mg weekly for 12 weeks (n=2) or BHV-1300 1000 mg SC weekly for 4 weeks followed by 500 mg SC weekly for 8 weeks. Values of TRAb below the limit of quantification (LOQ) were set to LOQ/2. DEGRADERS 10 15 20 25 30 35 40 45 Change from Baseline Free T4 Normal Adult Range 11.0 – 21.0 pmol/L 0 2 4 6 8 10 12 14 16 18 20 TRAb Change from Baseline 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Change from Baseline Free T3 BHV-1300 RAPIDLY REMOVES >80% OF TSHR AUTOANTIBODIES the root cause of Graves’ disease 1,000 mg SC weekly dosing TSHR Autoantibody Free T4 Free T3 Normal Adult Range 3.1 – 6.0 pmol/L 0 2 4 6 8 10 12 0 2 4 6 8 10 120 2 4 6 8 10 12 Weeks Post-Dose 1
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYBHV-1300 Rapidly Normalizes Thyroid Hormones in Patients With Graves’ Hyperthyroidism November 2026 Biohaven Corporate Presentation15 0 0.2 0.4 0.6 0.8 1 0 1 2 3 4 5 6 7 S u rv iv a l P ro b a b il it y Kaplan-Meier Curve of Time to Normalization of Free T4 0 0.2 0.4 0.6 0.8 1 0 1 2 3 4 5 6 7 S u rv iv a l P ro b a b il it y Kaplan-Meier Curve of Time to Normalization of Free T3 Weeks Post-Dose 1 Preliminary data from ongoing study, analysis conducted April 8, 2026. Graphs represent t ime to normalization of Free T3 and Free T4 in participants (n=3) with Graves’ disease and overt hyperthyroidism at baseline administered BHV-1300 1,000 mg SC weekly for 12 weeks (n=2) or BHV-1300 1,000 mg SC weekly for 4 weeks followed by 500 mg SC weekly for 8 weeks (n=1). Free T4 Free T3 DEGRADERS In hyperthyroid patients receiving BHV-1300 1,000 mg SC weekly, Free T4 normalized within an average of 3 weeks and Free T3 normalized within an average of 5 weeks KEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Lead MoDE Degrader, BHV-1300 Enters Phase 3 November 2026 Biohaven Corporate Presentation16 26 weeks Biohaven IgG degrader Placebo Screening DEGRADERS DATA READOUT Study Design: Randomized, double-blind, placebo-controlled trial Population: Male and female adults with Graves’ disease Endpoints: Normal T3, T4 and TSH off ATD at week 26 KEY STUDY DETAILS Normal TSH, T3, T4 (26 Weeks) off ATD ATD, antithyroid drugs BHV-1300 pivotal trial in Graves’ disease initiatedKEY POINT
Validates Biohaven’s extracellular protein degrader technology Leverages Ono’s immunology and endocrinology heritage and commercial leadership in the region C O L L A B O R A T I O N Translating scientific breakthroughs into medicines that matter Strongest and fastest path to patients in Japan and key Asian markets ~20% ROYALTY $100M NEAR-TERM Up to
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY BHV-1400 Gd-IgA1 Gd-IgA1 TRAP DEGRADER: BHV-1400 Targeting the Root Cause of IgA Nephropathy
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYBy the Time IgAN Is Diagnosed, Kidney Function Is Already Significantly Compromised November 2026 Biohaven Corporate Presentation19 IgAN 1. Pitcher. Kidney Int. 2023. IgAN predominantly affects people in their MOST PRODUCTIVE YEARS OF LIFE IgA nephropathy A rare chronic kidney disease that is caused by excess production of galactose-deficient IgA1 (Gd-IgA1) antibodies in the kidneys At diagnosis, kidney function is already reduced to 30–59% OF NORMAL CKD STAGE 3 M O S T C O M M O N A T D I A G N O S I S IgAN demands rapid intervention and a therapy safe enough to last a lifetime 59% 30% 20s M E D I A N A G E A T D I A G N O S I S 1 30s M O S T C O M M O N A G E R A N G E 1 Camille Diagnosed with IgAN in 2020 at age 25 Every month matters — rapid intervention to preserve kidney function and limited remaining nephronsGOAL TREATMENT DEGRADERS
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY KDIGO Guidelines Focus on Removal of Pathogenic Gd-IgA1 November 2026 Biohaven Corporate Presentation20 DEGRADERS
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYBHV-1400: Selective Removal of Disease-Causing Gd-IgA1 Without Immunosuppression Compared to Market Competitors November 2026 Biohaven Corporate Presentation21 IgD IgEIgG Gd-IgA1 TARGET ENDOTHELIN RECEPTOR VANRAFIA®FILSPARI® INHIBIT COMPLEMENT SYSTEM WITH BROAD IMMUNOSUPPRESSION FABHALTA® ULTOMIRIS®SEFAXERSEN BROAD IMMUNOSUPPRESSION TARPEVO®TRAP Degrader BHV-1400 SELECTIVELY DEGRADES ONLY Gd-IgA1 Targeting the pathogenesis of disease without immunosuppression B C E L L S POVETACICEPT ATACICEPT FELZARTAMABVOYXACT® ZIGAKIBART MEZAGITAMABTARGET B CELLS WITH GLOBAL IMMUNOGLOBULIN SUPPRESSION IgM IgA DEGRADERS BHV-1400 is the only therapy designed to remove pathogenic Gd-IgA1, the root cause of IgAN, while preserving healthy immune function KEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY -80 -70 -60 -50 -40 -30 -20 -10 0 BHV-1400 500 mg SC Bi-Monthly Deeply and Selectively Removes Gd-IgA1 Without Suppression of Normal Healthy IgA in Patients With IgAN November 2026 Biohaven Corporate Presentation22 IgG IgA % c h a n g e f ro m b a s e li n e STABLE DAY 31 STABLE DAY 31 STABLE DAY 31 STABLE FROM BASELINE DAY 31 STABLE FROM BASELINE DAY 31 STABLE FROM BASELINE DAY 31 IgM DEGRADERS Day 3 n=5 Gd-IgA1 Day 17 n=6 Day 31 n=3 Preliminary data from ongoing study. Data represents mean % change in immunoglobulins in patients with IgAN administered one month of BHV-1400 500 mg every two weeks. Error bars represent standard error. % C h a n g e f ro m B a s e li n e ~ 4 8 H o u rs P o s t- D o s e -64% -71% -70% -80% -60% -40% -20% 0% 20% 0 10 20 30 -80% -60% -40% -20% 0% 20% 0 10 20 30 -80% -60% -40% -20% 0% 20% 0 10 20 30 Healthy Immunoglobulins Gd-IgA1
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY WARNINGS AND PRECAUTIONS Immunosuppression and Increased Risk of Infections VOYXACT suppresses the immune system by reducing antibody production, which may increase the risk of infections. Immunosuppression and Immunization Risks Because of its mechanism of action, VOYXACT may interfere with the immune responses to vaccines and increase the risk of infection from live vaccines. Competitors Show Long-Term Immunosuppression1,2 November 2026 Biohaven Corporate Presentation23 1. Competitors did not report IgE. 2. All competitor data presented herein are derived from publicly available sources only. Certain data points have been reconstructed or estimated from published graphical information. No confidential, non-public, or proprietary information was used. This analysis has not been reviewed or validated by the referenced companies. 3. Solid dots represent the mean of the maximal total IgG % change from baseline 4. Barratt. American Society of Nephrology Kidney Week 2025. Poster FP-PO0808. 5. Lafayette. Kidney International. 2024 6. Lafayette. NEJM. 2025. 7. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761434s000lbl.pdf VOYXACT SC2,6 Weeks -80% -70% -60% -50% -40% -30% -20% -10% 0% 10% 20% 0 5 10 15 20 25 30 35 40 45 50 -80% -70% -60% -50% -40% -30% -20% -10% 0% 10% 20% 0 5 10 15 20 25 30 35 40 45 50 -80% -70% -60% -50% -40% -30% -20% -10% 0% 10% 20% 0 5 10 15 20 25 30 35 40 45 50 35% DROP FROM BASELINE WEEK 48 75% DROP FROM BASELINE WEEK 48 69% DROP FROM BASELINE WEEK 48 38% DROP DAY 30 16% DROP DAY 30 42% DROP DAY 30 Atacicept 150 mg2,5 Weeks -80% -70% -60% -50% -40% -30% -20% -10% 0% 10% 20% 0 5 10 15 20 25 30 35 40 -80% -70% -60% -50% -40% -30% -20% -10% 0% 10% 20% 0 5 10 15 20 25 30 35 40 -80% -70% -60% -50% -40% -30% -20% -10% 0% 10% 20% 0 5 10 15 20 25 30 35 40 35% DROP FROM BASELINE WEEK 36 75% DROP FROM BASELINE WEEK 36 64% DROP FROM BASELINE WEEK 36 36% DROP DAY 30 16% DROP DAY 30 44% DROP DAY 30 V O Y X A C T F D A L A B E L7 IgG IgA IgM Mezagitamab 600 mg SC2,4 Months 30% DROP FROM BASELINE MONTH 36 62% DROP FROM BASELINE MONTH 36 61% DROP MONTH 4 30% DROP MONTH 4 -80% -70% -60% -50% -40% -30% -20% -10% 0% 10% 20% 0 10 20 30 40 -80% -70% -60% -50% -40% -30% -20% -10% 0% 10% 20% 0 10 20 30 40 IgM Data not Reported DEGRADERS
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Drug de-challenge Drug re-challenge 0 1 2 3 H e m a tu ri a BHV-1400 Hematuria Case Report: De-Challenge Re-Challenge Recaptures Complete Hematuria Resolution November 2026 Biohaven Corporate Presentation24 DOSE DAY 1 DOSE DAY 15 DOSE DAY 29 3+ 1+ Resolved 2+ DOSE DAY 192 Resolved 1 17 31 45 51 173 192 235 DAY DOSE DAY 206 DOSE DAY 220 DOSE DAY 234 • Re-treatment with BHV-1400 500 mg every two weeks initiated upon disease recurrence after extended off-treatment period • Complete resolution of hematuria re-achieved within weeks of reinitiation KEY POINTS DEGRADERS
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY BHV-1400 Phase 1b IgA Nephropathy Patient Cohort — Safety Summary November 2026 Biohaven Corporate Presentation25 z • 10 participants with IgA nephropathy • Most AEs were mild and self-resolving • No treatment discontinuations for adverse events • No clinically significant trends in vitals, ECGs, or labs (including AST/ALT/Tbili) • No clinical evidence of cardiovascular, renal, hepatic, or hematologic toxicity • Preservation of IgA, IgG, IgM, IgE • No SAEs, severe AEs, or AEs resulting in discontinuation of therapy DEGRADERS Preliminary data from ongoing study, analysis conducted May 22, 2026.
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Lead TRAP Degrader BHV-1400 Planned Phase 3 Initiation in 2026 November 2026 Biohaven Corporate Presentation26 DEGRADERS Study Design: Randomized, double-blind, placebo-controlled trial Population: Male and female adults with biopsy-proven IgAN Dose: 500 mg self-administered via autoinjector Endpoints: ∆ UPCR, ∆ in eGFR, ∆ in Gd-IgA1 at week 52 KEY STUDY DETAILS 52-week Treatment Phase BHV-1400 (n=280) Placebo (n=140) Screening BHV-1400 OL 52 Weeks DATA READOUT BHV-1400 pivotal trial in IgA nephropathy initiating in 2026KEY POINT Updated
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY OPAKALIM Kv7 ACTIVATOR ION CHANNEL Revolutionizing Epilepsy Treatment With a Modern Kv7 Activator SELECTIVE Kv7 ACTIVATOR: OPAKALIM
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY An Epilepsy Treatment Designed With Patients and Physicians in Mind November 2026 Biohaven Corporate Presentation Opakalim offers potential for easy-to-use, once-daily treatment with no titration to control seizures without the burdensome side effects frequently reported with approved ASMs and those in development Selectively activates Kv7.2/7.3 channels—a validated MOA for treating epilepsy—without impacting GABA receptors Exhibits preliminary efficacy signals in focal epilepsy OLE, KCNQ2-DEE and now idiopathic generalized epilepsy Demonstrates exceptional safety profile with low rates of CNS adverse events across all trials (1300+ subjects) • Announced exclusive global license with SK Biopharmaceuticals • 1st focal epilepsy study topline expected 2H2026 BREAKING NEWS 28
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Idiopathic Generalized Epilepsy Time-to-Event Study Design Kv7 Study Design: Randomized, double-blind, placebo-controlled, event-driven trial Endpoint: Primary - Time-to-event (Event = 2nd day with GTC seizure), Secondary - GTC seizure freedom Population: Subjects 18–75 with IGE and intractable GTC seizures Key Entry Criteria: 3 GTC seizures within the historic 16-week seizure assessment period KEY STUDY DETAILS Up to 45 Days Screening Randomization (1:1) Double-blind Phase 24 weeks Opakalim 75 mg Placebo OLE Phase Opakalim 75 mg Study terminated early due to enrollment and strategic portfolio prioritization; GTC: generalized tonic-clonic; IGE: idiopathic generalized epilepsy; TTE: t ime-to-event 0 GTC seizures Completes 24 weeks Enters OLE ✓ 1 GTC seizure 1st GTC Completes 24 weeks Enters OLE ✓ 2 GTC seizures 1st GTC 2nd GTC EVENT TTE endpoint Exits double-blind Enters OLE Week 0 Week 24 Time-to-Event Endpoint: Scenarios November 2026 Biohaven Corporate Presentation29
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Demographics and Baseline Disease Characteristics Opakalim 75 mg n=15 Placebo n=12* Age (mean) 37 43 Sex (% female) 73% 83% Region (% US) 47% 25% BMI (mean) 27 28 Number of epilepsy treatments at screening 1 to 2 60% 67% 3 to 4 40% 33% Number of previous and current ASMs ≤ 6 11 (73%) 10 (83%) > 6 4 (27%) 2 (17%) Age at IGE diagnosis (mean) 14 13 Years since IGE diagnosis (mean) 23 30 Kv7 * In placebo group, 1 subject did not have post-dose efficacy data November 2026 Biohaven Corporate Presentation30 Highly treatment-resistant idiopathic generalized epilepsy populationKEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY 0 20 40 60 80 100 120 140 160 Placebo Opakalim Opakalim Prolongs Time-to-2nd GTC Seizure Days 141DAYS 47DAYS OPAKALIM n=15 PLACEBO n=11* Kv7 * In placebo group, 1 subject discontinued early due to study termination and 1 discontinued early due to AE M E D I A N T I M E - T O - 2 N D G T C S E I Z U R E November 2026 Biohaven Corporate Presentation31 3x LONGER FOR SUBJECTS ON OPAKALIM VS. PLACEBO Efficacy signal observed in idiopathic generalized epilepsy populationKEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Opakalim Prolongs Time-to-2nd GTC Seizure and Time in Double-Blind Kv7 Days in Double-Blind Phase Individual Subjects OPAKALIM PLACEBO 1st GTC E n d o f D o u b le -B li n d P h a s e 0 20 40 60 80 100 120 140 160 180 November 2026 Biohaven Corporate Presentation32
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Opakalim Prolongs Time in Double-Blind and Enhances Seizure Control November 2026 Biohaven Corporate Presentation33 33% of Opakalim-Treated Subjects Completed Six-Month Double-Blind Phase Without 2nd GTC 0 10 20 30 40 C o m p le ti o n R a te W it h o u t 2 n d G T C ( % ) Opakalim n=15 Placebo n=11* 33% 0% 0 10 20 30 40 C o m p le ti o n R a te W it h o u t 2 n d G T C ( % ) Opakalim n=15 20% 20% of Opakalim-Treated Subjects Completed Double-Blind Phase Seizure Free * In placebo group, 1 subject discontinued early due to study termination and 1 discontinued early due to AE Placebo n=11* 0% Kv7
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Our patient has very difficult-to-treat IGE, since entering the opakalim trial, she has experienced reduction in all seizure types. In terms of tolerability, she continues to do very well, with no adverse events. November 2026 Biohaven Corporate Presentation34 Promising Case of Broad-Spectrum Generalized Seizure Efficacy 42 3 0 0 10 20 30 40 50 Screening Double-blind Open-label GTC 8 0 0 0 2 4 6 8 10 Screening Double-blind Open-label Myoclonic 159 68 3 0 50 100 150 200 Screening Double-blind Open-label Absence 43-day SCREENING phase 50-day DOUBLE-BLIND phase (opakalim 75 mg) 125-day OLE phase Opakalim IGE Double-Blind Phase topline data, 1H 2026 • 50% of subjects with myoclonic seizures became myoclonic seizure free on opakalim • 33% of subjects with absence seizures became absence seizure free on opakalim KEY POINTS Kv7
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Efficacy Signal Demonstrated in KCNQ2-DEE 12 0 6 6 Baseline End of hospitalization 3-month follow-up 6-month follow-up S e iz u re C o u n t 50% reduction in seizures on overnight EEG 9-year-old boy with • Refractory KCNQ2-DEE • Kv7 activation-dependence • Heterozygous for Kv7.2 G281E mutation • Daily tonic seizures at baseline despite 3 ASMs including 1st gen Kv7 activator • Prior attempts to taper 1st gen Kv7 activator resulted in status epilepticus, ICU admission and developmental regression Kv7 Olson. AAN 2026. Poster #P10 11-002; Equivalent exposures to 75 mg dose in pivotal focal epilepsy studies N o rm a li z e d C u rr e n t a t -5 0 m V (% o f W T K v 7 .2 /7 .3 , 0 .1 % D M S O ) 300 250 200 150 100 50 0 0.1% DMSO 0.1% DMSO 1 µM opakalim 1 µM ezogabine Mutant Cells (Kv7.2G281E) Wild-type November 2026 Biohaven Corporate Presentation35 Successfully transitioned from 1st gen Kv7 to opakalim and stable for 6+ monthsKEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Efficacy Signal Observed in Focal Epilepsy Open-Label Data Kv7 RISE 2 Part B: opakalim 75 mg;; Opakalim ongoing focal epilepsy preliminary data 1H 2026 for open-label 6-month completers; French. Epilepsia Open. 2025; Indirec t comparisons between compounds based on publicly available data. As part of the nonclinical charac terization of certain metabolites of opakalim observed in rodent test ing, an update was prov ided to global regulatory authorities regarding these ongoing s tudies. I t was determined that there was insufficient information related to a specific metabolite to assess its risk to human subjects. The FDA ins tructed Biohaven to pause new enrollment until additional clarifying nonclinical s tudies are completed and issued a partial clinical hold letter on September 4, 2026. BREAKING NWS November 2026 Biohaven Corporate Presentation36 SEIZURE FREQUENCY Pretreatment Baseline in OP SEIZURE FREQUENCY On Treatment with Opakalim 75 mg in OLE vs. >54% OF PATIENTS SHOWED OVER ANY CONSECUTIVE 6-MONTH PERIOD IN OLE (n>100) 50% RESPONSE RATE RISE 3 RISE 2* Double-blind Phase 8-Weeks OLE Phase Observation Phase (OP) Opakalim 75 mg 50% RR for opakalim (54%) comparable to azetukalner (56%)KEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Preferred Term Opakalim 50 mg Opakalim 75 mg Opakalim Pooled Headache 4.5% 6.4% 5.7% Nasopharyngitis 4.5% 6.4% 5.7% Seizure 5.3% 3.7% 4.3% Dizziness 3.0% 5.0% 4.3% Fatigue 3.0% 4.1% 3.7% Fall 2.3% 4.6% 3.7% Upper respiratory tract infection 3.0% 4.1% 3.7% Back Pain 3.8% 3.2% 3.4% Insomnia 5.3% 2.3% 3.4% Nausea 3.8% 2.8% 3.1% Diarrhea 6.0% 1.4% 3.1% Exceptional Tolerability Observed in Focal Epilepsy Open-Label Data Kv7 Adverse events reported in ≥3% of pooled participants, opakalim ongoing focal epilepsy open-label preliminary data 1H 2026 November 2026 Biohaven Corporate Presentation37 Low incidence, majority mild and spontaneously resolvedKEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY 4% 6% 3% 4% <1% - - 4% 4% 3% <1% <1% 0%5%10%15%20%25%30% 25% 19% 17% 15% 11% 11% 10% 10% 9% 6% 6% 0 5% 10% 15% 20% 25% 30% Opakalim Demonstrates Favorable Tolerability vs. Azetukalner in Focal Epilepsy Open-Label Trials Incidence (%) Kv7 Opakalim ongoing focal epilepsy open-label preliminary data 1H 2026; percentages rounded to the nearest whole percent; Azetukalner focal epilepsy data from Open Label Study – French. AES 2025. Poster #3.356. Opakalim Azetukalner Dizziness Headache Somnolence Fall Memory impairment Weight gain Gait disturbance Seizure/change in seizure Fatigue Nausea Balance disorder Diplopia November 2026 Biohaven Corporate Presentation38
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY 3% 2% 5% 3% 4% 17% 25% 19% 6% 9% 25% 23% 10% 12% 23% 25% 25% 13% 13% 23% 26% 24% 11% 11% 24% 0% 5% 10% 15% 20% 25% 30% Somnolence/Tiredness Dizziness Headache Nausea/Upset Stomach Fatigue/Sleepiness Opakalim Azetukalner Cenobamate Lacosamide Levetiracetam Opakalim Demonstrates Favorable Tolerability vs. Approved and Investigational ASMs P e rc e n t o f S u b je c ts R e p o rt in g A d v e rs e E v e n t Dizziness Headache Fatigue / sleepiness Naus / upset stomach Somnolence / tiredness Opakalim Azetukalner Cenobamate Lacosamide Levetiracetam Opakalim ongoing focal epilepsy open-label preliminary data 1H 2026; Azetukalner data from Open Label Study – French. AES 2025. Poster #3.356; Cenobamate, lacosamide and levetiracetam data from Winter. CNS Drugs. 2024. Kv7 November 2026 Biohaven Corporate Presentation39
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY50% Responder Rate in OLE Trials of Several Approved and Investigational ASMs 40 Opakalim Azetukalner Brivaracetam Cenobamate Eslicarbazepine Lacosamide Perampanel 20% 30% 40% 50% 60% 70% 80% 37% 53% 33% 56% 48% 72% 34% 60% 54% 44% 53% 63% 56% Opakalim ongoing focal epilepsy open-label preliminary data 1H 2026; Hufnagel. Epilepsy Res. 2013; Halász. Epilepsia. 2010; Strzelczyk. Epilepsia. 2021; Ben-Menachem. Epilepsy Res. 2021; O’Brien. Epilepsia. 2020; Klein. Neurology. 2022; Strzelczyk. Expert Rev Clin Pharmacol. 2015; Husain. Epilepsia. 2012; French, J. Epilepsia Open. 2025; Rektor. Epilepsia. 2020. Kv7 November 2026 Biohaven Corporate Presentation Opakalim OLE preliminary efficacy outcomes fall within reported range of responder rates for other ASMs in OLE trials KEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYOpakalim Is Easy-to-Use With a Projected Favorable Tolerability Compared to Approved ASMs No titration Favorable CNS tolerability Low neuropsychiatric AEs Low metabolic / electrolyte AEs Low SJS or DRESS risk L 1 Lamotrigine ✘✘ ✓ ✓ ✓ ✘✘ Levetiracetam ✓ ✓ ✘ ✓ ~ Oxcarbazepine ✘ ✘ ✓ ✘ ✘ L 2 Lacosamide ✘ ✓ ✓ ✓ ✓ Eslicarbazepine ✘ ✘ ✓ ✘ ~ Brivaracetam ~ ✘ ✘ ✓ ✓ L 3 Zonisamide ✘ ✘ ✘ ✘ ✓ Cenobamate ✘✘ ✘ ✓ ✓ ✘✘ Topiramate ✘ ✘ ✘ ✘ ✓ Opakalim (Kv7) ✓ ✓ ✓ ✓ ✓ November 2026 Biohaven Corporate Presentation41 ✓ Favorable ~ Variable ✘ Unfavorable ✘✘ Very Unfavorable AE, Adverse Event. SJS, Stevens-Johnson Syndrome. DRESS, Drug Reaction with Eosinophilia and Systemic Symptoms Kv7
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY P A Y M E N T S T O B I O H A V E N $400M Upfront: $350M at Closing, $50M one year after Closing Contingent development and regulatory milestones$150M Up to Mid-teens to low twenties Tiered US opakalim royalties; mid-single-digit outside the US SK Biopharmaceuticals | Biohaven Global License for Opakalim November 2026 Biohaven Corporate Presentation42 • First Korean company to independently discover, develop and commercialize a novel antiseizure medicine • XCOPRI® marketed in the US for partial-onset (focal) seizures in adults • SKBP CEO: Opakalim is "a highly complementary addition to our epilepsy portfolio" 30+ years of history 150+ professionals in a dedicated US neurology field force Double-digit steady growth of XCOPRI® Biohaven and SKBP: advancing selective Kv7 activation in epilepsy THE TEAM THAT LAUNCHED XCOPRI® Additional deal terms assumed by SKBP • Go-forward costs SKBP to fund specified Kv7 program costs • Up to $245M Milestones to Knopp assumed by SKBP; separate from SKBP's payments to Biohaven Royalties are subject to specified reductions and adjustments. Source: Biohaven Form 8-K and Exhibit 99.1 (August 26, 2026). XCOPRI is a registered trademark of SKBP. HSR waiting period has cleared and the parties are coordinating on the closing. Both parties have agreed to close the transaction on December 3, 2026, in accordance with the terms and conditions of the agreement
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY TALDEFGROBEP / MYOSTATIN COMPLEX Targeting High-Quality Weight Loss in Obesity MYOSTATIN ACTIVIN PATHWAY INHIBITOR: TALDEFGROBEP ALFA
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Targeting High-Quality Weight Loss With Myostatin-Activin Inhibition Taldefgrobep directly targets fat and muscle while avoiding intolerable adverse effects Novel myostatin-activin MOA for healthy weight loss Inhibits ActRII signaling in muscle and adipose tissue Favorable safety profile established in >700 treated to date Low rates of muscle- and GI-related AEs Convenient dosing Administration by subcutaneous autoinjector TALDEFGROBEP FAT MUSCLE November 2026 Biohaven Corporate Presentation44 • Phase 2 study in obesity ongoing with planned addition of GLP-1 combination cohort • Topline data from monotherapy and GLP-1 combination therapy arms expected 2H 2027 BREAKING NEWS
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Taldefgrobep Is a Novel Competitive Inhibitor of ActRII Signaling November 2026 Biohaven Corporate Presentation45 NON-PRODUCTIVE RECEPTOR BINDING of the Taldefgrobep/Myostatin complex to ActRII receptor TALDEFGROBEP/ MYOSTATIN COMPLEX ActRII ALK 5/7 LEAN MUSCLE MASS FAT MASS SMAD 2/3 Signaling Inhibited Activins A, C, E Myostatin GDF11 blocks both free myostatin AND activin signaling at the receptor level ActRII LIGANDS REGULATING FAT AND MUSCLE METABOLISM ALK 4 TALDEFGROBEP TALDEFGROBEP Taldefgrobep binds ligands and competitively inhibits receptor activation in tissues where myostatin and multiple activins (e.g., A, C, E) are active KEY POINT ActRII, activin type II receptors. ALK 4/5/7, activin (type I) receptor-like kinases. GDF11, growth and differentiation factor 11
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Unmet Needs Remain in Obesity Management Despite New Therapies November 2026 Biohaven Corporate Presentation46 Taldefgrobep targets the limitations of current therapies, offering a novel and differentiated solution for patients living with obesity KEY POINT Increase muscle mass and bone density while reducing fat mass Including metabolically-active VAT Minimal or no clinically meaningful adverse events Suitable for chronic administration Support convenient dosing Potential for monthly dosing in an easy- to-use autoinjector for better adherence Opportunity in obesity management: TALDEFGROBEP Unprecedented reductions in total body weight are limited by: Significant muscle loss Up to 40% of GLP-1-induced weight loss is lean mass1,2 Increased Risk for Fractures Pelvic fractures were 4–5x more common on Wegovy vs. PBO3 Intolerable adverse events Two-thirds stop GLP-1 therapy within 1 year4 1. Wilding. N Engl J Med. 2021. 2. McCrimmon. Diabetologia. 2020. 3. Wegovy USPI. Update NOV 2025. Accessed 29-DEC-2025. 4. Prillman. Scientif ic American. 2024. VAT, Visceral Adipose Tissue.
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYClinical Data Has Validated Myostatin Activin Inhibitor Class Uncovering Optimal Profile for Efficacy and Safety in Obesity MOA Directly Targeting Fat Reduction Weight Loss Favorable Safety Profile Potential SC Monthly Dosing Adipose Tissue Skeletal Muscle Taldefgrobep (Biohaven) Bimagrumab Activin Receptor Blocker (Lilly) ✕ ✕ Apitegromab*, SRK439 Anti-Myostatin (Scholar Rock) ✕ ✕ ✕ ✕ Trevogrumab* Anti-Myostatin (Regeneron) ✕ ✕ ✕ ✕ Trevogrumab + Garetosmab* Anti-Myostatin + Anti-Activin A (Regeneron) ✕ ✕ ✕ WVE-007, ARO-INHBE, ARO-ALK7 Activin E or ALK7 siRNA (Wave, Arrowhead) ✕ November 2026 Biohaven Corporate Presentation47 *Apitegromab, Trevogrumab and Trevogrumab + Garetosmab Phase 2 studies were conducted in combination with a GLP-1 agent. Taldefgrobep offers optimal mechanistic profile for efficacy and safety KEY POINT TALDEFGROBEP
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYMyostatin Activin Pathway Inhibition Demonstrates Benefits in Total Body Weight, Fat and Muscle BELIEVE: 1-Year Trial of Bimagrumab in Adults Living with Overweight or Obesity November 2026 Biohaven Corporate Presentation48 Placebo Bimagrumab (30 mg/kg iv) Semaglutide (2.4 mg sc) Combination (bima + sema) EFFICACY Total body weight (W48) -2.5% -9.7% -14.3% -20.2% Total fat mass (W48) -5.2% -25.3% -24.8% -42.2% Total lean mass (W72) -0.5% 2.5% -7.4% -2.9% Visceral Adipose tissue (W48) -2.1% -40.2% -29.5% -54.8% TALDEFGROBEP Exceeds 5% differential guideline set by the FDA Change comparable to semaglutide Preservation/improvement in lean mass Greater reduction in metabolically- active VAT vs. semaglutide Taldefgrobep targets bimagrumab-like efficacyKEY POINT VAT, Visceral Adipose Tissue.
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Percent Change in Cholesterol From Baseline at 48 Weeks Bimagrumab Provides Reason To “Believe” With Compelling Efficacy but Limited by Safety/Tolerability Placebo Bimagrumab (30 mg/kg IV) Semaglutide (2.4 mg SC) Muscle Spasms 5.5% 73.7% 8.9% Diarrhea 5.5% 49.1% 35.7% Acne 3.6% 43.9% 8.9% Poor tolerability due to irreversible ActRIIB binding Elevation in lipids secondary to high peak exposures following IV administration Heymsfield. Nature Medicine. 2026. Weeks since randomization Bimagrumab 30 mg/kg Semaglutide 2.4 mg Placebo -20 -10 0 10 20 30 0 10 20 30 40 50 % C h a n g e i n t o ta l c h o le s te ro l -20 -10 0 10 20 30 0 10 20 30 40 50 % C h a n g e i n t o ta l L D L - c h o le s te ro l TALDEFGROBEP November 2026 Biohaven Corporate Presentation49
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYTaldefgrobep Avoids GI- and Muscle-Related AEs Commonly Reported in Bimagrumab Clinical Trials November 2026 Biohaven Corporate Presentation50 Muscle-/GI-Related AEs Taldefgrobep SAD/MAD Pooled1 15-180 mg n=103 Bimagrumab 30 mg/kg2 Single Dose Study n=10 Bimagrumab 10 mg/kg3 Q4W Multi-dose Study n=37 Acne 0% 30% 3% Muscle spasm 3% 30% 41% Musculoskeletal stiffness 0% 30% NA Myalgia 1% 30% NA Muscle weakness 1% 10% NA Diarrhea 2% 10% 41% Nausea 1% NA 11% Lipase level increased 0% 0% 11% NA = data not available 1. Study CN001001 conducted in healthy adults receiving taldefgrobep (15-180 mg QW x 1 month). 2. Garito. Diabetes Obes Metab. 2018. 3. Heymsfield. JAMA Network Open. 2021. TALDEFGROBEP Favorable safety profile established in >700 participants across diverse clinical populationsKEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYTaldefgrobep/Myostatin Complex Competes With Activin Signaling To Improve Muscle Differentiation and Fat Storage November 2026 Biohaven Corporate Presentation51 TALDEFGROBEP T/M Complex Inhibits Activin-Induced Signaling Through ActRII with taldefgrobepno taldefgrobep MUSCLE MATURATION FAT STORAGE MITOCHONDRIAL MASS Activin A Activin E Activin A only 12.5 nM complex 25 nM complex Activin E only 12.5 nM complex 25 nM complex N o rm a li ze d p S M A D 2 /3 ( a s a % o f li g a n d o n ly ) *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 BODIPY MF20 TOM20 DAPI N o rm a li ze d p S M A D 2 /3 ( a s a % o f li g a n d o n ly ) The T/M complex, at clinically relevant exposures, inhibits activin A- and activin E-induced ActRII signaling KEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Change in Total Body Weight, From Baseline at 8 Weeks Change in Fat Mass From Baseline at 8 Weeks Change in Lean Muscle Mass From Baseline at 8 Weeks In an Obese Mouse Model, Taldefgrobep Demonstrated Significant Reductions in Fat Mass While Increasing Lean Mass November 2026 Biohaven Corporate Presentation52 n=15 for vehicle; n=16 for all other groups. Error bars represent standard error of the mean. Significance evaluated using Tukey’s multiple comparisons test. **P < 0.01; ***P < 0.001; ****P < 0.0001; QD, once daily; taldefgrobep alfa. Bechtold. ObesityWeek 2024. Poster 350. Taldefgrobep demonstrated reductions in fat mass and increases in lean mass as monotherapy and in combination with a GLP-1 receptor agonist KEY POINT TALDEFGROBEP -6 -4 -2 0 2 4 6 8 C h a n g e i n T o ta l B o d y W e ig h t (% ) **** **** C h a n g e i n L e a n M u s c le M a s s ( % ) -5 0 5 10 15 20 25 **** ** **** **** C h a n g e i n F a t M a s s ( % ) 20 -40 -20 0 **** *** ** Vehicle Taldefgrobep Semaglutide (40 µg/kg QD) Taldefgrobep + Semaglutide (40 µg/kg QD)
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYTaldefgrobep Improves Body Composition in Non-Obese Adults With Potential for Monthly Dosing in Obesity November 2026 Biohaven Corporate Presentation53 TALDEFGROBEP Peak Plasma Concentrations of Taldefgrobep-Myostatin Complex Occurs 20-30 Days Post Dose 1 10 100 1000 0 12 24 36 48 60 72 84 96 M e a n ( S D ) C o n c e n tr a ti o n ( n g /m L ) Time (day) Bound Myostatin In Healthy Adults at One Month Post Dosing, Taldefgrobep Demonstrates: 0 1 2 3 4 0 5 10 15 20 25 30 35 40 45 50 55 LAST DOSE % C h a n g e F ro m B a s e li n e 29 7 Days Lean Body Mass Continued INCREASE IN LEAN MASS -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 0 5 10 15 20 25 30 35 40 45 50 55 LAST DOSE % C h a n g e F ro m B a s e li n e Fat Body Mass Continued DECREASE IN FAT MASS Placebo Taldefgrobep 45 mg LAST DOSE Taldefgrobep-myostatin complex increases lean mass and also directly inhibits Activin E / ALK7 signaling in adipose tissue KEY POINT 29 7 Days
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Safety database includes more than 700 treated trial participants Assessed across a wide dose range (4 mg to 180 mg SC QW) and broad demography Data from repeat dosing up to 192 consecutive weeks Taldefgrobep Has an Established, Favorable Safety Profile November 2026 Biohaven Corporate Presentation54 LOW RATES of SAEs and AEs leading to discontinuation LOW RATES of GI- and muscle- related AEs commonly reported with other myostatin-activin pathway inhibitors No identified serious signature clinical safety events TALDEFGROBEP Safety profile well-suited for indication in chronic weight managementKEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Ongoing Phase 2 Monotherapy Dose-Ranging (Q1W + Q4W) Study November 2026 Biohaven Corporate Presentation55 24-Week DBT Period 4 Weeks Randomization (n~150) Randomization (2:2:1:1) 8 Weeks Post-Dose Follow-Up Taldefgrobep Q1W Taldefgrobep Q4W 24-Week OLETaldefgrobep 100 mg Q1W (n=50) Placebo Q1W (n=25) Taldefgrobep 150 mg Q4W (n=50) Placebo Q4W (n=25) Study Design: Phase 2, randomized, double-blind, placebo-controlled dose-ranging study Population: Male and female adults (18 to 65 years old) with overweight or obesity Blinded Interim Analysis (when 30% complete Week 12): Taldefgrobep PK/PD (free myostatin and T/M complex concentrations) and plasma lipids by treatment assignment Endpoints: % change in total body weight, fat mass and lean mass at Week 24. Whole-body MRI in subset KEY STUDY DETAILS TALDEFGROBEP PART A: Monotherapy Planning to initiate Part B evaluating taldefgrobep + GLP-1 combinationKEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY 113.59 107.78 115.4 116.57 95 100 105 110 115 120 125 130 Baseline Week 12 205.89 196.74 206.87 195.97 185 190 195 200 205 210 215 Baseline Week 12 126.04 119.74 126.3 120 110 115 120 125 130 135 Baseline Week 12 Blinded Interim Data by Q1W vs. Q4W, Taldefgrobep + Placebo No Adverse Effects on LIPIDS at Week 12 Error bars represent standard error Total Cholesterol LDL Cholesterol Triglycerides • No treatment-emergent G2-4 elevations in total cholesterol or triglyceride values • 1 participant with emergent G3 LDL elevation; had G2 elevation at baseline Q1W n=27 Q4W n=30 Q1W n=27 Q4W n=30 Q1W n=27 Q4W n=30 November 2026 Biohaven Corporate Presentation56 TALDEFGROBEP No identified adverse trends in lipid parameters demonstrating differentiated safety from other myostatin-activin pathway inhibitors KEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY 0 20 40 60 80 100 % M y o s ta ti n S u p p re s s io n F ro m B a s e li n e 100 mg Q1W 150 mg Q4W 100 mg Q1W 150 mg Q4W Interim Phase 2 PK/PD Data Supports Weekly and Monthly Dosing in Obesity November 2026 Biohaven Corporate Presentation57 AT WEEK 12: • Observed mean taldefgrobep concentrations are consistent with model-predicted • Robust suppression of free myostatin throughout Q1W and Q4W dosing intervals • T/M complex concentrations comparable between dosing regimens and at/above target ActRII IC50 TALDEFGROBEP % Myostatin Suppression at Week 12 in Overweight/Obese Adults Taldefgrobep-Myostatin Complex at Week 12 in Overweight/Obese Adults 99% 79% 4.74 9.48 6.44 12.88 2 4 6 8 10 12 14 T /M C o m p le x ( n M ) 100 mg Q1W 150 mg Q4W ActRII IC50 Low Estimate: 4.74 High Estimate: 9.48 Low Estimate: 6.44 High Estimate: 12.88 Interim data suggest monthly dosing can achieve robust myostatin suppression and formation of T/M complex levels at/above targeted ActRII IC50 levels KEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Visceral adipose tissue loss favorable to GLP-1 therapies Increase in bone density favorable to GLP-1 therapy Favorable safety and tolerability Taldefgrobep Offers a Novel Approach To Address the Needs for People Living With Obesity November 2026 Biohaven Corporate Presentation58 Total body weight loss meeting current regulatory standards Increase in lean muscle mass highly differentiated from GLP-1 therapies Benefit as monotherapy and in combination with GLP-1 therapies TALDEFGROBEP Convenient subcutaneous autoinjector with potential for monthly dosing Fat mass loss comparable to GLP-1 therapies
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYTaldefgrobep Can Benefit a Broad Spectrum of People Living With Obesity November 2026 Biohaven Corporate Presentation59 TALDEFGROBEP Source: BHVN Market Research and Analytics Data on file 5–7M People living with BMI ≥40 5–10M People unable to tolerate high dose GLP-1 6.6M–10M Older patients at risk of sarcopenia 5–8M People intolerant or refractory to GLP-1 M O N O T H E R A P Y G L P - 1 A D J U N C T Meaningful reductions in fat mass, preservation of lean muscle mass, once-monthly dosing and high tolerability drive market potential KEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Modular Next-Generation ADC Technologies: Optimizing for Clinical Performance ONCOLOGY
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYInnovative Biohaven Technologies Enabling Differentiated Next-Generation ADCs 61 Clinical Proof-of-Principle Establishing the Power and Flexibility of the Platform to Optimize Across a Broad Range of ADC Designs and Combination Strategies Including CPI ONCOLOGY First clinical demonstration (BHV-1510 Trop2) Highly stable, differentiated PK and safety, compelling activity with CPI combination Pioneering FGFR3 ADC (BHV-1530) Novel mAb, potential to address both FGFR3 alterations and overexpression Platform tech enables multi-class payload loading Clinically differentiated TopoIx payload, foundational for CPI and other potentially synergistic MOA combinations NEXT-GEN MODULAR ADC CONJUGATION TECHNOLOGIES OPTIMIZED MONO AND BISPECIFIC MABS PROPRIETARY TOPOIX AND MULTI- CLASS PAYLOADS O N H November 2026 Biohaven Corporate Presentation • BHV-1510: Robust enrollment in endometrial + cemiplimab combination expansion cohort • BHV-1530: First activity observed, including pretreated FGFR3-altered urothelial cancer patient; combination cohort with Libtayo now enrolling under clinical supply agreement with Regeneron. • Discovery: Preclinical data supporting next-wave bispecific mAb, multi-payload formats NEWS BREAKING
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYBHV-1510 + Cemiplimab Leads to Rapid, Deep and Durable Responses in Heavily Pretreated Patients, Majority With Prior Anti-PD(L)1 November 2026 Biohaven Corporate Presentation62 P e rc e n t c h a n g e i n s u m o f ta rg e t le s io n m e a s u re m e n ts ( % ) 2 mg/kg Q3W 2.5 mg/kg Q3W 2.75 mg/kg Q3W1.25 mg/kg D1 D8 Q3W 1.5 mg/kg D1 D8 Q3W Weeks on therapy 2 mg/kg Q3W 2.5 mg/kg Q3W 2.75 mg/kg Q3W 1.25 mg/kg D1 D8 Q3W 1.5 mg/kg D1 D8 Q3W Partial Response Stable Disease Progressive Disease Complete Response Continuing Treatment BHV-1510 + Cemiplimab*: Percent Change in Target Lesions BHV-1510 + Cemiplimab: Treatment Duration *Cemiplimab (anti-PD1) provided through a supply agreement with Regeneron; dose of cemiplimab 350 mg Q3W Source: Micaily. ESMO Immuno-Oncology Congress 2025. Poster 252P. Patients on treatment at 6 months and beyond Majority (87.1%) had prior anti-PD(L)1 exposure ONCOLOGY
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY BHV-1510 Demonstrates a Favorable PK Profile With Highly Stable ADC November 2026 Biohaven Corporate Presentation63 2 mg/kg Q3W 2.5 mg/kg Q3W 2.75 mg/kg Q3W BHV-1510 payload ANALYTE DOSE M e a n ( S D ) c o n c e n tr a ti o n ( n g /m L ) Nominal time (day) MONO COMBO 0 7 14 21 0 7 14 21 BHV-1510 (ADC) and Payload Concentration-Time Plots for Cycle 1 (with or without Cemiplimab) Source: Micaily. ESMO Immuno-Oncology Congress 2025. Poster 252P. ONCOLOGY The unconjugated payload concentration was low with a payload-to-ADC molar ratio <1%, indicating that ADC was highly stable in the circulation KEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYEncouraging Early Clinical Activity and High Response Rates of BHV-1510 + Cemiplimab Enable First Tumor-Specific Expansions • Dose escalation complete: Compelling efficacy in difficult-to-treat patients • Responses in heavily pretreated patients, including with brain metastases; majority with prior anti-PD(L)1 exposure • Rapid onset of benefit: Tumor shrinkage / PRs at 1st scan • Differentiated safety profile: Low rates of hematological toxicities and diarrhea; no ILD observed* • Favorable PK profile: Highly Stable ADC November 2026 Biohaven Corporate Presentation64 P e rc e n t c h a n g e i n t a rg e t le s io n f ro m b a s e li n e ( % ) Non-Small Cell Lung Cancer Endometrial Cancer Urothelial Carcinoma Weeks on therapy BHV-1510 2.5 mg/kg + Cemiplimab Q3W: Target Lesion Change From Baseline * By independent adjudication Source: Micaily. ESMO Immuno-Oncology Congress 2025. Poster 252P. ONCOLOGY • Early data suggests synergy with anti-PD-1 and potential to move into earlier lines • Endometrial cancer expansion cohort with combination enrolling robustly — data to inform pivotal path KEY POINTS
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY FGFR3 Overexpression and Alteration (%) in Urothelial Carcinoma BHV-1530: Favorable Early Clinical Profile — No FGFR-Class Toxicities and Early Signs of Antitumor Activity Compelling preclinical efficacy across FGFR3-altered and FGFR3-overexpressing tumor models: Demonstrated as monotherapy and in combination with CPI Clinical progress: First patient dosed April 2025: initial cohorts successfully completed: • No dose limiting toxicities • No treatment-related SAEs • TRAEs predominantly mild (Grade 1–2) • No hyperphosphatemia, nail disorders, central serous retinopathy Early signs of activity: Early tumor reduction in patients with FGFR3 alterations and wild-type overexpression, as dosing in the predicted efficacious range November 2026 Biohaven Corporate Presentation65 51% Upper Tract UC 70–80% Non-muscle-invasive BC 40–60% Muscle-invasive BC ~50% of HNSCCFGFR3 ~ 40% of NSCLC 4–8% alterations in other cancers ~50% Metastatic UC As of April 2026. Data from ongoing study ONCOLOGY • Combination cohort with Libtayo now enrolling under clinical supply agreement with Regeneron • Early tumor reductions in FGFR3-altered and WT overexpressing patients, including urothelial cancer • Dose escalation continuing with no DLTs to date KEY POINTS
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY BHV-1530: Phase 1 Study in Advanced Tumors November 2026 Biohaven Corporate Presentation66 ORR, Overall Response Rate; PFS, Progression Free Survival; ADA, Antidrug Antibody; BOIN, Bayesian Optimal Interval; RD, Recommended Dose. RD KEY ELIGIBILITY PHASE 1 Dose escalation following BOIN design Study Design: Open label, dose escalation (Ph1) Population: Advanced UC, HNSCC, NSCLC having failed SOC therapy Treatment Duration: Until disease progression or toxicity Endpoints: Safety and tolerability, ORR, PFS, PK and ADA KEY STUDY DETAILS Select advanced refractory tumors (FGFR3 expression level not required for study entry) Dose Level Higher dose Higher dose ONCOLOGY Early tumor reduction in patients as dosing in the predicted efficacious rangeKEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Case Narrative: Metastatic Urothelial Cancer • 28 y/o female with urothelial cancer with a FGFR3::TACC3 fusion, with metastasis to lungs and thoracic lymph node • 4 prior lines of therapy including • Padcev and Keytruda and 2 FGFR targeting small molecules-Balversa and LOXO-435 • Tolerating treatment with mild nausea and no FGFR related toxicity 67 Baseline Week 12 Baseline Week 12 November 2026 Biohaven Corporate Presentation ONCOLOGY
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY 68 BHV-1530: Potential First FGFR3 ADC — Broader Reach, No Class Toxicities, Clear Development Path PH1 DOSE ESCALATION NOW • ACTIVE • No DLTs; no FGFR-class toxicities • Early tumor reduction in altered + WT overexpressing DOSE OPTIMIZATION+POC • Identify recommended Ph2 dose • UC expansion POC • Confirm activity across FGFR3 subtypes COMBO EXPANSION • Expansion cohort in UC with CPI combo • Pivotal design conversations begin 1L mUC - PIVOTAL PATH • 1L mUC combination with CPI • Monotherapy in 2L+-selected pts BHV-1530 ADC vs. Small-Molecule FGFR3 Inhibitor Small Molecule Inhibitor BHV-1530 Target Population FGFR3-altered only ~limited addressable population Altered AND overexpressing — full FGFR3+ population Class Toxicities Hyperphosphatemia nail disorders, retinopathy None observed — no FGFR inhibitor-class toxicities Mechanism Kinase inhibition resistance develops readily ADC: targeted delivery of cytotoxic payload CPI Combination Limited — overlapping toxicity concerns Engineered for CPI synergy TopoIx → ICD → DEVELOPMENT ROADMAP November 2026 Biohaven Corporate Presentation 3x larger TAM in mUC (15-20% are FGFR3 altered and up to 50% are altered/or overexpressed)
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY BHV-8000 Leveraging Validated Immune Targets To Stop Neuroinflammation BRAIN-PENETRANT TYK2/JAK1 INHIBITOR: BHV-8000
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Brain-Penetrant TYK2/JAK1 Inhibitor To Treat Parkinson’s Disease 70 BHV-8000 addresses the widespread immune dysregulation that drives the onset and progression of neurodegenerative disorders Suppresses innate and adaptive immune cell activation and infiltration High selectivity for TYK2/JAK1 avoids JAK2/3 safety liabilities Demonstrated target engagement, robust brain penetration and a promising safety profile TYK2/JAK1 Phase 2/3 trial in early-stage PD ongoing November 2026 Biohaven Corporate Presentation
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Widespread Immune Dysregulation Is a Hallmark of PD November 202671 1. Sulzer. Nature. 2017. 2. Wissemann. Am J Hum Genet. 2013. 3. Li. Front Immunol. 2023. 4. Tansey. Nat Rev Immunol. 2022. 5. Potashman. Parkinsonism Relat Disord. 2025. 6. Roodveldt. Brain. 2024. 7. Karikari. Brain Behav Immun. 2022. 8. Williams. Brain. 2021. 9. Yacoubian. Mov Disord. 2023. 10. Pajares. Cells. 2020. 11. Qu. npj Parkinsons Dis. 2023. 12. McGeer. Neurology. 1988. • Misidentification of self-proteins (⍺-synuclein) as foreign antigen triggers immune response1 • GWAS studies link PD risk to HLA gene variants involved in antigen presentation2 PD meets criteria for autoimmunity based on pathophysiology and genetics • Epidemiological studies suggest immune dysfunction and inflammation are key to the development of PD4 • Reduction in rates of PD have been seen when this population is exposed to immune-modulating therapies5 Epidemiology reveals increased risk of PD in individuals with other autoimmune diseases3 • In mouse models, T cells specific to α-synuclein peptides can induce dopaminergic neuronal loss7 • Manipulation of immune components (T cells) affect α-synuclein-induced neurodegeneration8 PD animal models demonstrate immune dysregulation drives neurodegeneration6 PD patient samples and imaging exhibit characteristic proinflammatory signatures9,10 • Proinflammatory cytokines (e.g., IL-6, TNF-⍺, IFNƔ) are found in CSF and blood of PD patients11 • PD brains express high levels of HLA-DR+ reactive microglia12 TYK2/JAK1 Biohaven Corporate Presentation
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYBHV-8000 Reduces Glial Activation, Increases Neuronal Survival, and Improves Function in AAV-⍺-syn Mouse Model of Parkinson’s Disease 72 Increased Time on Rotarod by: Increased Movement Distance in an Open Field by: Sham Model BHV-8000 (10 mg/kg) BHV-8000 (30 mg/kg) *p<0.05, **p<0.01, ***p<0.001, Mean ± SEM A C C L I M A T I O N Immunostaining Behavioral assessments AAV-⍺-SYN injection BHV-8000 dosing 10 and 30 mg/kg BID -7 1 3 45DAY 42 AAV-α-synuclein Mouse Model Increased the Survival of TH+ Neurons in the Substantia Nigra: Reduced the Number of Activated Glial Cells (Iba1+) in the Substantia Nigra: TYK2/JAK1 BHV-8000 reduces inflammation and improves neurological functionKEY POINT November 2026 Biohaven Corporate Presentation Reduced Inflammation Increased Neuronal Survival Improved Function N u m b e r o f Ib a 1 + c e ll s p e r s e c ti o n N u m b e r o f T H + c e ll s p e r s e c ti o n D is ta n c e i n o p e n f ie ld ( m ) T im e o n R o ta ro d ( s )
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYBHV-8000 Demonstrates Target Engagement, Robust Brain Penetration and a Promising Safety Profile in Phase 1 Studies 73 BHV-8000 Brain Exposures at 20 mg QD EC50 Modeling data Phase 1 program completed • Includes SAD/MAD study in healthy adults Well-tolerated • No SAEs or severe AEs • No adverse laboratory trends related to study drug Evidence of target engagement • Reduced plasma inflammatory cytokines downstream of TYK2 (IP-10, IFNβ) and JAK1 (hsCRP, IFNβ) Robust brain penetration • Exposures in CNS approximately 50% of plasma concentrations TYK2/JAK1 Brain exposure sustained above target EC50s for 24 hours at clinical dosesKEY POINT November 2026 Biohaven Corporate Presentation
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY MDS-UPDRS, Movement Disorder Society – Unified Parkinson’s Disease Rating Scale; CGI-S, Clinician Global Impression of Severity scale; PARCOMS, Parkinson’s composite scale that includes most sensit ive items from MDS-UPDRS and PDQ-39. 48-Week Time-to-event BHV-8000 20 mg PO Once Daily BHV-8000 10 mg PO Once Daily Placebo 56-Days 48-Weeks Screening Extension Study BHV-8000: Phase 2/3 Study in Early Parkinson’s Disease Ongoing November 202674 TYK2/JAK1 Time-to-event design enables efficient trial KEY POINT Biohaven Corporate Presentation Study Design: Phase 2/3, randomized 1:1:1, double-blind study Population: Early untreated PD Endpoints: Primary: Time to qualifying worsening event on MDS-UPDRS Part II Secondary: Change in MDS-UPDRS Part III, CGI-S, DaT-SPECT, PARCOMS composite scale KEY STUDY DETAILS
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Targeting Brain Hypometabolism to Treat Neurodegenerative Diseases BRAIN-PENETRANT PKM2 ACTIVATOR: BHV-8100
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY The Brain Has Considerable Energetic Requirements 2% of body mass 15% of cardiac output 25% of whole-body glucose utilization 20% of oxygen consumption Y E T DISCOVERY November 2026 Biohaven Corporate Presentation76
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Healthy Adults Alzheimer's disease º º Aerobic Glycolysis Is Reduced in the Aging Brain • Aerobic glycolysis, the metabolic process of glucose primarily promoted by astrocytes in the brain, is reduced in the aging brain1 • Reduction of aerobic glycolysis is pronounced in frontal and temporal regions2 1. Goyal. Cell Metab. 2017. 2. Vlassenko. Clin Transl Imaging. 2015. Images (left to right) comparing the cortical distribution of elevated AG and task-induced activity decreases in the DMN in normal with areas of decreased glucose metabolism and Aβ plaque accumulation in patients with AD DISCOVERY November 2026 Biohaven Corporate Presentation77
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYActivation of Pyruvate Kinase Increases Glucose Consumption and ATP Production While Reducing Deleterious Metabolism • BHV-8100 stabilizes enzymatically active tetramer state • Increased energy in CNS • Decreased neuroinflammation, angiogenesis and fibrosis • Reduced deleterious metabolic intermediates More Active State Increased Glycolysis Increased Energy Less Active State Immune Activation Biomass Production Fibrosis PKM2 DIMER PKM2 TETRAMER BHV-8100 Source: Cancer Letters. 2015. Increased biosynthesis of cellular building blocks PYRUVATE PYRUVATE PKM2 DIMER PKM2 TETRAMER ATP LDH Lactate ↑ Respiratory chain ↑ ATP production GLUCOSE PEP ADP DISCOVERY November 2026 Biohaven Corporate Presentation78
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY BHV-8100: First Brain-Penetrant PKM2 Activator Oral small molecule medicine with multiple potential indications Neurodegeneration Neuroinflammation Brain ischemia Retinal degeneration and inflammation Age-related changes: central/peripheral DISCOVERY November 2026 Biohaven Corporate Presentation79 First-in-human dosing at pharmacologically relevant doses initiated 2Q 2026KEY POINT Peripheral inflammation
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYBHV-8100: Experimental Mitigation of Neuroinflammation and Restoration of Energetic Deficiency DISCOVERY November 2026 Biohaven Corporate Presentation80 BHV-8100 Shows Robust Reduction of Disease Burden in EAE Distance TraveledClinical Score (EAE Therapeutic Model) * p < 0.05, ** p < 0.01, *** p < 0.001 relative to CPZ group, MCC950 is an NLRP3 inhibitor. BHV-8100 Demonstrates Striking Efficacy in Cuprizone Model Myelin-Basic Protein in Corpus Callosum EAE BHV-8100 15mpk EAE BHV-8100 30mpk EAE BHV-8100 100mpk EAE BHV-8100 300mpk BHV-8100 10mpk BID BHV-8100 30mpk BID BHV-8100 100mpk BID BHV-8100 60mpk QD BHV-8100 demonstrates anti-inflammatory efficacy and a strong ability to promote oligodendroglial function in models of EAE KEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYBHV-8100 Demonstrates Sustained Efficacy in Human Brains With Documented Alzheimer’s Disease and All-cause Dementia Reperfused human brains (Brainex ) allow precise study of brain penetrance, pharmacology, pharmacokinetics, pharmacodynamics and biomarkers in brains with documented diseases November 2026 Biohaven Corporate Presentation81 DISCOVERY Disease of Cognitive Impairment1: BHV-8100 Enhances Glucose Uptake Alzheimer’s Disease: BHV-8100 Enhances Glucose Uptake Alzheimer’s Disease: BHV-8100 Enhances Lactate Production 1. Diverse diagnoses including AD and other disease. Precise determinations of brain penetrance and dose-response pharmacology confirm efficacy and guide human dosage KEY POINT
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORYEarly FIH Data of BHV-8100 in SAD Shows Safety and Tolerability in Healthy Participants Preliminary data from ongoing Phase 1 Study BHV8100-101 (as of 29-May-2026) DISCOVERY November 2026 Biohaven Corporate Presentation82 No SAEs or severe AEs Most AEs mild and spontaneously resolving No clinically significant ECG changes No clinically significant trends in safety labs including LFTs PK allows QD dosing & achieves projected efficacious exposures
November 2026 Biohaven Corporate Presentation83 Financial Update CGRP $151.1M 2 $164M1 1. Includes cash, cash equivalents and marketable securities as of September 30, 2026; 2. As of October 26, 2026. 3. Cap reached if aggregate annual US net sales of rimegepant and zavegepant amount to $8.15B. Royalty payments would be in respect of years ended on or before 12/31/40. $500M
Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY November 2026 Biohaven Corporate Presentation84 2H 2026 1H 2027 2H 2027 GLUTAMATE Troriluzole | BHV-4157 Spinocerebellar Ataxia INFLAMMATION & IMMUNOLOGY Gd-IgA1 Degrader | BHV-1400 IgA Nephropathy IgG Degrader | BHV-1300 Common Disease (Graves’, RA) TYK2/JAK1 Inhibitor | BHV-8000 (brain- penetrant) Parkinson’s Disease MYOSTATIN ACTIVIN Taldefgrobep Alfa | BHV-2000 Obesity ION CHANNEL Kv7 Activator | Opakalim Focal Epilepsy ONCOLOGY Trop2 ADC +/- PD-1 | BHV-1510 Advanced or Metastatic Epithelial Tumors FGFR3 ADC +/- PD-1 | BHV-1530 Urothelial Cancer and Other Tumors Key Milestones Anticipated in 2026 - 2027 Phase 2 Topline (inc GLP-1 Combo) Pivotal Topline Ongoing Phase 2/3 Trial Initiate Pivotal IgAN Trial Ongoing Expansion Cohort in Endometrial Cancer Ongoing Phase 1 in Urothelial Cancer Ongoing Pivotal Graves’ Trial NDA Resubmission Accepted AdCom PDUFA Target Action Date